What is BHRT and how do I know if I need it?

Short answer BHRT = bioidentical hormone replacement therapy. It means replacing hormones (usually estradiol/estrogen, progesterone, and sometimes testosterone) with compounds that have the same chemical structure as human hormones. It’s used most often for menopausal or perimenopausal symptoms (hot flashes, night sweats, vaginal dryness, low libido) and for some people with age‑related low testosterone. Whether you “need” it depends on your symptoms, medical history, and risk factors — a clinician should evaluate you and discuss benefits, risks and alternatives.

What BHRT is, in plain language

• “Bioidentical” refers to hormones that are chemically identical to human hormones (for example, 17β‑estradiol, micronized progesterone).
• BHRT can be prescribed as FDA‑approved products (patches, pills, vaginal tablets/gels, injections) or made by compounding pharmacies (custom creams, pellets, combinations).
• Delivery options: transdermal patch or gel, oral pills, vaginal tablets or rings, injections, and subcutaneous pellets.

How BHRT is different from other hormone therapy

• Conventional HRT may use the same bioidentical molecules (many common estrogen and progesterone products are bioidentical) or synthetic/animal‑derived progestins.
• The major distinction often discussed is compounded (non‑FDA) “custom” BHRT vs. FDA‑approved preparations. FDA products have quality control and standardized dosing; compounded products do not have the same regulatory oversight and may be less predictable.

Who might be a candidate

• Menopausal or perimenopausal people with bothersome vasomotor symptoms (hot flashes, night sweats) or urogenital symptoms that affect quality of life.
• People with premature ovarian insufficiency or surgical menopause.
• Men or women with clinically confirmed low testosterone and related symptoms (low libido, low energy), after careful assessment.

When BHRT is generally not recommended (important contraindications)

• Active or recent breast cancer (unless cleared by oncology), estrogen‑sensitive cancers without oncology approval.
• Unexplained vaginal bleeding.
• Active or history of venous thromboembolism (blood clots), recent stroke or heart attack (needs specialist evaluation).
• Untreated severe liver disease.
  Always discuss risks with your clinician.

What the evidence and risks say (brief)

• BHRT can effectively reduce hot flashes, night sweats and help vaginal dryness; testosterone can help sexual function in some women.
• Risks depend on hormone type, dose, route and the person’s age/risk profile. Transdermal estrogen has lower clot risk than oral; combined estrogen‑progestin was associated with increased breast cancer and cardiovascular risks in some studies (risks vary by age and timing of start). Long‑term outcomes are individualized and should be discussed with your clinician.

Typical evaluation and monitoring

• Clinical history and symptom assessment; family history of breast/ovarian cancer; cardiovascular risk assessment.
• Baseline recommended tests often include: mammogram (if due), blood pressure, fasting lipid panel, glucose/A1c, and possibly hormone labs (estradiol, FSH, total testosterone, SHBG) — note: hormone levels fluctuate in perimenopause and are not always definitive. For some therapies (compounded testosterone), monitoring serum levels is used.
• Ongoing monitoring: symptom response, side effects, regular mammography and pelvic care as recommended, periodic reassessment of dose/need.

Alternatives or adjuncts

• Nonhormonal treatments for hot flashes: SSRIs/SNRIs (venlafaxine, paroxetine), gabapentin, clonidine, lifestyle changes.
• Local vaginal estrogen (vaginal tablet/creams/rings) for urogenital symptoms with minimal systemic absorption.
• Lubricants/moisturizers for vaginal dryness.

Brands and services (recommendations and why)

• Estradiol patches: Vivelle‑Dot, Climara — transdermal delivery reduces first‑pass liver effects and tends to have lower VTE risk than oral estrogen.
• Vaginal/local estrogen: Vagifem (vaginal tablets), Estring or other local rings — effective for local vaginal atrophy with low systemic exposure.
• Micronized progesterone: Prometrium — an FDA‑approved bioidentical progesterone option commonly used for endometrial protection with estradiol.
• Testosterone gels (when appropriate and prescribed): AndroGel, Testim — used more often in men; testosterone therapy for women is off‑label and requires specialist oversight and monitoring.
• For reliable, evidence‑based care and evaluation: Mayo Clinic Menopause Clinic, Cleveland Clinic Menopause Program, or any clinician certified or listed by the North American Menopause Society (NAMS) — these centers follow guidelines and can individualize care.
• If considering compounded BHRT: use only accredited compounding pharmacies (look for those accredited by the Pharmacy Compounding Accreditation Board/PCAB) and discuss with a clinician experienced in BHRT; be aware compounded products are not FDA‑approved and dose/absorption can vary.

How to decide next (practical steps)

1. Make a list of symptoms, duration, how they affect daily life, and any medications and major medical history (clots, breast cancer, heart disease).
2. Schedule an appointment with your primary care clinician, gynecologist, endocrinologist or a menopause specialist (NAMS‑listed). Ask about risks/benefits tailored to you.
3. If you and your clinician decide to try BHRT, prefer FDA‑approved preparations when possible and start with the lowest effective dose; arrange baseline screening (mammogram, labs) and a monitoring plan.
4. If considering compounded BHRT or pellet therapy, discuss the limited evidence and quality variability and get labs and follow‑up monitoring set up.

If you want, tell me:

• your age, sex/gender, main symptoms, and relevant medical history (breast cancer, blood clots, heart disease), and I can outline what a clinician will likely check and what options may be appropriate for you.